Landsman A, Roukis TS, DeFronzo DJ, Agnew P, Petranto RD, Surprenant M, et al.
Wounds : a compendium of clinical research and practice. Date of publication 2008 May 1;volume 20(5):111-6.
1. Wounds. 2008 May;20(5):111-6.
Living cells or collagen matrix: which is more beneficial in the treatment of
diabetic foot ulcers?
Landsman A(1), Roukis TS, DeFronzo DJ, Agnew P, Petranto RD, Surprenant M.
Author information:
(1)Harvard Medical School, Boston, Massachusetts; Email:
alandsma@bidmc.harvard.edu.
In a randomized multicenter study, 26 subjects with diabetes, neuropathy, and
foot ulceration were treated with standard local wound care and application of
either a living skin equivalent [LSE] (Dermagraft®, Advanced BioHealing, La
Jolla, Calif) or extracellular matrix [ECM] collagen wound dressing (OASIS® Wound
Matrix, Healthpoint, Fort Worth, Tex). Subjects were analyzed to confirm that the
wounds, demographics, and health characteristics of subjects in each group were
equivalent. Depending on the randomization, subjects received up to 3
applications of LSE or 8 applications of ECM. Subjects received this treatment in
conjunction with standard saline dressings for a maximum of 12 weeks, and were
observed for 20 weeks. No statistically significant difference was found in the
size, distribution, or characteristics of the wounds evaluated in each group.
There was no statistically significant difference in the time to closure or the
rate of closure between the two groups. Similarly, no significant adverse events
were reported in either group. The results of this study show comparable healing
rates with use of either material. Further, it was hypothesized that both
collagen and cellular components are necessary, and it is suggested that various
conditions may make one or the other material more desirable.
PMID: 25942411
